Digipath
Home > Boards > US OTC > Biotechs >

InventaBioTech Inc. (INVB)

INVB RSS Feed
Add INVB Price Alert      Hide Sticky   Hide Intro
Moderator: zen222, m1999, Quintessence, TAB78, joe117, UkranianWolf
Search This Board: 
Last Post: 1/16/2019 8:13:02 PM - Followers: 21 - Board type: Free - Posts Today: 0

logo
(INVB) WestMountain Asset Management, Inc. Reverse Merger with CytoBioscience, Inc.

just changed their name to InventaBioTech, Inc.


InventaBioTech, Inc. website: http://inventabiotech.com/index.html


Share structure
Authorized Shares 100,000,000 
Outstanding Shares  54,798,761 (Over 53 million are restricted)
Float 761,750 
https://www.otcmarkets.com/stock/WASM/security 
 



 
InventaBioTech's instrument is used by the FDA in its safety pharmacology studies and there isn’t any real competition. 
Our patch clamp robot is the gold standard in accurate and reliable data while saving massive amounts of time and money. 
Videohttps://youtu.be/g2yahi4VJJs
Cytocentric's patch clamp robot. Image courtesy Cytocentric.

CytoPatch – the “hands-free” manual patch platform

Gigohm seals without enhancers
Data quality of manual 
patch clamp
Can be a collection solution for analytical support
The platform 
chosen by the FDA

The Cytopatch is a robotic AI patch clamp platform designed to mimic a manual patch rig. This platform offers cell capture and sealing with quartz glass electrodes, seal resistances of 2 G? or greater without the need for seal enhancers, recordings at physiologic temperatures, and perfusion of the well for multiple concentration exposures. Because of its high data quality, flexibility, and throughput, the CytoPatch is an excellent choice for any lab wanting the performance of a manual patch clamp rig but with a much-enhanced throughput.

Routine applications include: recording ion currents in expression systems and recording ion currents and action potentials in iPS-CM or native adult cardiac myocytes. Because of its unique perfusion system, data can be obtained from difficult to record currents such as ligand-activated currents and currents which desensitize rapidly.

The Cytopatch is the choice for anyone who wants the power of a manual patch clamp setup with the throughput of an automated platform at a competitive price. 

The base CytoPatch unit sells for $175,000, and InventaBioTech also sells microchips, buffers, solutions, cells, and specific types of shipping containers to researchers on a recurring basis, Garvin says. CytoBioscience, which changed its name last year, was founded in Germany and moved to San Antonio in 2015. Regulatory filings show CytoBioScience had raised about $15.8 million as of August 2016. 
They just did a $1.5 million non-dilutive offering so they're flush with cash now. ($1.53 million equity round of funding) 
From the 8K - "Each of these revenue-generating segments; instruments, consumables and contract research, is a leader in its technology and in its capacity. Having undergone years of testing, starting, restarting, and honing its development into the cutting edge it is today, the Company is experiencing accelerating revenue growth and is well-positioned to reach its potential."
 
Also: "The market is experiencing strong growth, driven by both regulation and rising demand for outsourced safety pharmacological work.
The company is engaged with both private and public partners globally, including the FDA."

 

Image result for cytobioscience inc
CytoBioscience's latest acquisition: SolubleBioScience: https://solublebioscience.com/

 
CytoBioScience has 4 locations:
San Antonio, TX
New Orleans, LA
Birmingham, AL
Cologne, Germany


Contact info
Dr. James Garvin, PhD  

E-mail: info@InventaBioTech.com

(210)-767-2727
 
 
Company Officers and (B Of D) : 
 
James R. Garvin, PhD, Chief Executive Officer, President and Director 
James R. Garvin has served as the CEO, President and a Director of CytoBioscience since March 2015. Dr. Garvin has twenty-nine years of experience in working in the biotech sector and finance. His work has been recognized by the French Academy of Science and he was named one of sixteen
healthcare innovators in the state of Texas for 2017. As a former investment banker, he has worked on a number of different biotechnology acquisitions, in the US, Europe and in Israel. He has been a board member of a number of companies and currently is on the board of the Zerah Foundation which provides educational opportunities for underprivileged children in India. His international range of experiences and interests has been diverse but this has allowed him to have an outside of the box perspective that has served him well in working with companies and situations over the years. 
Dr. Garvin received his
PhD in Economic Systems from the University of New Orleans, as well as his Masters in Administration and his BA (Hons) in English and International Relations from the State University of New York, Albany 

Thomas Knott,
PhD, Chief Science Officer 
Thomas Knott,
PhD has served as the Chief Science Officer of CytoBioscience since March 2015. Dr. Thomas Knott is an innovative technology driven entrepreneur who founded Cytocentrics CCS GmbH, a high-tech scientific instrumentation and biotech company specializing in the field of ion channel electrophysiology in 2001. Dr. Knott single-handedly developed the Cytocentrics instrument for ion channel analysis, the CytoPatch™, demonstrating a more complete feature set in patch clamp capabilities than any existing manual patch clamp system (whole cell voltage clamp and current clamp, perforated patch clamp, extracellular and intracellular perfusion, temperature control, fast ligand gated ion channels, mechano-stimulation, GLP, and network capability). He has worked with three Nobel Prize-winning teams. 

Henry C. Bourg, CPA, MBA, Chief Financial Officer 
Henry C. Bourg, CPA, MBA, has served as the CFO of CytoBioscience since September 2017. Henry Bourg is an accomplished senior finance and accounting professional with over thirty years' experience with start-ups, mid-sized and multi-billion dollar global organizations. He started his career with Ernst & Young in Texas and later in Maryland and New York. While with Ernst & Young, he served primarily financial institution clients such as American General Life Insurance, Capital One 
and MBNA America Bank. In addition to his public accounting experience, Henry has served in senior finance and accounting roles with the US Government in Europe; The Shaw Group, Chicago Bridge & Iron, and Westinghouse Electric Company in Asia; Inktomi Corporation and Bookham, Inc. (now Oclaro) as well as several technology start-ups in Silicon Valley. He earned his Bachelor of Science degree in Accounting from Louisiana State University and a Master of Business Administration from Santa Clara University . 

Paul Castella,
PhD, MBA, Director 
Dr. Paul Castella is the co-founder and CEO of Santalis Pharmaceuticals, Inc. a clinical stage drug development company. Santalis is a wholly owned subsidiary of Quintis Ltd., which acquired the business in 2015, along with ViroXis Corporation (which Paul co-founded in 2008). Previously, Paul co-founded and managed a number of other life science businesses, including; CardioSpectra, Inc., which was acquired by Volcano Corporation (NASDAQ: VOLC) in December 2007; Xenotope Diagnostics, Inc., which developed the only FDA approved rapid test for Trichomonas (sold worldwide under the OSOM ® brand), the world's most prevalent non-viral sexually transmitted disease; BiO2 Medical, Inc., which developed the Angel ® Catheter, the first device indicated for the prevention of pulmonary embolism (PE) in hospitalized patients; and the San Antonio-based Targeted Technology Funds, which focus on early-stage life science investing, including an investment in CytoBioscience. 
Paul received his
PhD in cell biology and genetics from Cornell University Medical College in Manhattan, his MBA from the University of Texas at San Antonio, a BSc (Hons) in biochemistry the University of London, and has been granted ten US patents. 

Ian Clements, MSc., Director 
Ian Clements has over 25 years of commercial, corporate and business development experience in the pharmaceutical and biotechnology industries including sales and marketing, medical affairs, product and clinical development, program management as well as commercial, corporate and business development. 
Ian is the co-founder and COO of Santalis Pharmaceuticals and the co-founder and former CEO of ViroXis Corporation. Ian served for six years as Head of Commercial Operations and Corporate Development for ILEX Oncology in San Antonio where he established the new Business Development and Medical Affairs departments during the launches of Campath and
Clorfarabine. Previously, Ian has served as the Head of Oncology Product Management at Lederle labs in UK, Head of Global Oncology Product Management at the Upjohn company where he managed the global launch of Camptosar and Head of US Oncology Marketing for Novartis, managing their oncology portfolio with over $2 billion in sales and launching 3 oncology products in his tenure. 
Ian received his BS (Hons) degree in Genetics from Swansea University, UK and his MS. in Immunology from King's College, London, UK. 

Alan Dean, MBA, Director 
Alan Dean is a senior technology executive with over 40 years of experience in the technology development industry. He was employed for more than 25 years at Southern Research Institute where he became Vice-President, Commercialization, and was a principal in the first commercial spin-off companies from the Institute. As the co-founder and COO of SBS, one of the subsidiaries in the holding company he co-founded, Alan was responsible for the buyout and integration of Birmingham Polymers, Inc., a Bristol-Myers-Squibb affiliate. SBS was subsequently acquired by
Durect Corp. of California in 2001 in a transaction valued at $35 million. He has been an advisor to, and board member of, numerous technology companies, past and present. Alan is the co-founder and senior managing partner of the Targeted Technology Fund I and II, and was previously a Managing Partner of the Birmingham Technology Venture Fund. 

Shing Leong Hui, MBA, Director 
Shing Leong Hui has over thirty years' experience in the Electronics Manufacturing Services Industry. He is currently the Chairman of the Supervisory Board of Payer International Technologies GmbH where he has served since June 2002. He is the co-founder of Neutronics Electronic Industries Holding A.G., which has been subsequently acquired by Flex Ltd. (previously known as Flextronics) and was a previous Flextronics board member. Today, he is widely involved with companies which are based in Eastern Europe and China. He has a long association with Cytocentrics and was one of the original investors when it was based in Rostock, Germany. 
He has an MBA from the University of Michigan and a B.Sc in Chemical Engineering from the University of Birmingham, UK. 

Sue Lynn Hui, Director 
Sue Lynn Hui has over six years of European and Asian experience in the Pharmaceuticals, Communications
and Technology and Oil and Gas sectors. She has served as an advisory member of Payer since March 2017. She was a Manager in her previous role at A.T Kearney from 2002 to 2007. She is an advisory board member of Payer International Technologies GmbH. 
She graduated with First Class Honors in Master of Engineering in Chemical Engineering from Imperial College London, UK. 

 

 
 
Digipath
INVB
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#1101  Sticky Note Name and Symbol change just showed up on zen222 12/31/18 01:42:42 PM
#1002  Sticky Note CytoBioscience: Microcap Play in the $55 Billion Life Quintessence 10/17/18 04:22:15 PM
#894  Sticky Note Trinity freshman Searches for Cancer Treatments (using CyoBioscience's Quintessence 09/03/18 11:03:28 AM
#1160   Here you go chemist72, directly from the website: zen222 01/16/19 08:13:02 PM
#1159   If only Dr. Garvin was quick to release UkranianWolf 01/16/19 07:22:32 PM
#1158   What is the big hold up here? chemist72 01/16/19 02:43:16 PM
#1156   Agreed. This one just requires much patience... Quintessence 01/14/19 01:45:00 PM
#1155   Yes it is. Have more invested here than HMB2010 01/14/19 01:43:06 PM
#1154   Good to see that Ask move up. Quintessence 01/11/19 11:05:17 AM
#1153   Agreed. Tempted to slap to that .55 HMB2010 01/11/19 11:02:36 AM
#1152   Yes, nice paint job! Does do wonders for Quintessence 01/11/19 10:46:43 AM
#1151   Now let's see something encouraging from the company. zen222 01/11/19 10:30:07 AM
#1150   LOL, INVB up over 100% today! chemist72 01/11/19 10:22:36 AM
#1149   Why no one bid higher than $.011?? chemist72 01/08/19 10:52:42 AM
#1148   Wow that would bring my avg down lol! HMB2010 01/07/19 06:20:01 PM
#1147   Hey, I'd grab some at that level if Quintessence 01/07/19 02:11:25 PM
#1146   Know what you mean. Bid now $.0101 - yuck! chemist72 01/07/19 02:10:29 PM
#1145   Ouch! One little trade makes my portfolio Quintessence 01/07/19 01:44:17 PM
#1144   Wouldn’t a RS cause this stock to be UkranianWolf 01/06/19 02:36:06 PM
#1143   Well, if a reverse were to happen I zen222 01/05/19 03:50:32 PM
#1142   I can think of couple reasons to delay RS. chemist72 01/05/19 01:56:27 PM
#1140   They will most likely reverse split. The Quintessence 01/05/19 01:36:16 PM
#1139   How will the RS be made effective? chemist72 01/05/19 01:31:23 PM
#1138   INVB also needs new 10-K by end of March. chemist72 01/05/19 11:46:22 AM
#1137   Their Edgar listing also needs to be updated. chemist72 01/05/19 11:40:15 AM
#1136   I second that motion. At least the contact chemist72 01/05/19 11:31:35 AM
#1135   Nice, I'd like to see them update OTCMarkets zen222 01/04/19 11:12:52 PM
#1134   Very nice. Thats the way it should be HMB2010 01/03/19 02:42:22 PM
#1133   http://inventabiotech.com is up and running, and updated with Quintessence 01/03/19 02:36:47 PM
#1132   Like a couple of good PR's and news!! HMB2010 01/02/19 08:00:24 PM
#1131   It wouldnt take much to get to 4, HMB2010 01/02/19 07:59:39 PM
#1130   If Garvin said so, that's good enough for me! chemist72 01/02/19 03:21:08 PM
#1129   Oh, I'm sure it's gone up some but zen222 01/02/19 03:01:18 PM
#1128   The float number I see on otcmarkets.com is chemist72 01/02/19 02:51:32 PM
#1127   It's difficult to say. I've just never seen zen222 01/02/19 02:21:00 PM
#1126   Dr. Garvin clearly stated so to me. but joe117 01/02/19 02:06:01 PM
#1125   Agree. Really would like to see a company chemist72 01/02/19 01:37:17 PM
#1124   I'd be really surprised if the Board voted chemist72 01/02/19 01:34:50 PM
#1123   Roger that. I believe the name and symbol zen222 01/02/19 01:34:11 PM
#1122   a reverse split would not have hurt the joe117 01/02/19 01:28:31 PM
#1121   Either way (with/without RS) INVB needs some giddy-up. lol chemist72 01/02/19 01:18:01 PM
#1120   No worries. From my experience, if a reverse zen222 01/02/19 01:14:05 PM
#1119   Sorry, for my imprecise wording in that post. chemist72 01/02/19 12:55:36 PM
#1118   No, I'm being dead serious. That is NOT zen222 01/02/19 12:36:58 PM
#1117   Your kidding me, right? chemist72 01/02/19 12:24:52 PM
#1116   What "reverse split" are you referring to? zen222 01/02/19 11:44:26 AM
#1115   Name changed and symbol changed on Ameritrade. chemist72 01/02/19 11:34:43 AM
#1114   Nice start!! HMB2010 01/02/19 11:27:38 AM
#1113   IDK. Haven't tried placing an order yet. chemist72 01/02/19 10:37:48 AM
#1112   Is it tradable yet? joe117 01/02/19 10:35:17 AM
#1111   Call me kooky but I figured the fact zen222 01/02/19 10:18:14 AM
#1110   Who will be the FIRST to trade INVB?? chemist72 01/02/19 09:52:53 AM
#1109   Starting off the brand spanking new year with zen222 12/31/18 11:46:01 PM
PostSubject